bluebird bio Adrenoleukodystrophy (ALD) Product Recognized in Science Magazine's Scientific Breakthroughs in 2009 Read more about bluebird bio Adrenoleukodystrophy (ALD) Product Recognized in Science Magazine's Scientific Breakthroughs in 2009
bluebird bio Appoints Mitchell Finer, Ph.D. as Chief Scientific Officer Read more about bluebird bio Appoints Mitchell Finer, Ph.D. as Chief Scientific Officer
bluebird bio Secures $35M in Series B Funding Read more about bluebird bio Secures $35M in Series B Funding
New Data From Adrenoleukodystrophy (ALD) Pilot Study Presented at American Society of Gene and Cell Therapy Show Three-Year Disease Stabilization of Patients Read more about New Data From Adrenoleukodystrophy (ALD) Pilot Study Presented at American Society of Gene and Cell Therapy Show Three-Year Disease Stabilization of Patients
Genetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer Read more about Genetix Pharmaceuticals Renamed bluebird bio; Announces Appointment of Nick Leschly as Chief Executive Officer
NATURE Publishes Promising Results on Treatment of First Patient in bluebird bio's Phase 1/2 Beta-Thalassemia Study Read more about NATURE Publishes Promising Results on Treatment of First Patient in bluebird bio's Phase 1/2 Beta-Thalassemia Study
bluebird bio Awarded Two Qualifying Therapeutic Discovery Project Program Grants Read more about bluebird bio Awarded Two Qualifying Therapeutic Discovery Project Program Grants
bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy Read more about bluebird bio and Généthon Announce Manufacturing Research Collaboration Centered on Lentiviral Vectors for Gene Therapy
Massachusetts Life Sciences Center Announces 2010 Tax Incentives Targeted at Read more about Massachusetts Life Sciences Center Announces 2010 Tax Incentives Targeted at
bluebird bio Awarded up to $4.2 Million from the French Muscular Dystrophy Association for Continued Development of Gene Therapy for Beta-Thalassemia and Sickle Cell Anemia Read more about bluebird bio Awarded up to $4.2 Million from the French Muscular Dystrophy Association for Continued Development of Gene Therapy for Beta-Thalassemia and Sickle Cell Anemia